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Table 1 Regression Analysis of Survival
Variable
Relatie Risk of Mortality
(95% Confidence Interval)
P-
Value
DONOR TYPE
MSD* 1.0
MURD 1.5(0.6-3.9) .35
MMURD 4.7(1.9-11.7) <.01
UCB 1.8(0.8-4.0) .15
LENGTH OF FIRST
REMISSION
< 1 year* 1.0
> 1 year 0.5(0.3-1.0) .05
ALL T-CELL LINEAGE
No* 1.0
Yes 2.6(1.1-6.2) <.01
GRADE II-IV ACUTE GvHD
No* 1.0
Yes 0.5(0.2-1.1) .07
* Reference Category
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DIRECTED DONOR CORD BLOOD TRANSPLANTATION FOR HEMATO-
LOGICAL DISORDERS
Walters, M.C.1, Quirolo, L.1, Edwards, S.1, Lee, J.1, Robertson, S.1,
Falcon, K.2, Briddell, R.2, Lubin, B.1 1Children’s Hosp & Research
Center Oakland, Oakland, CA; 2Viacell, Inc., Boston, MA.
The Sibling Connection Program is a directed donor cord
blood program that accommodates sibling cord blood banking
from remote collection sites in the US. Between September
1997 and September 2006, 65 children were treated by sibling
donor cord blood transplantation (CBT) utilizing these cord
blood units (CBUs), 51 using cord blood as the sole source of
allogeneic hematopoietic cells. CBT recipients had acute leu-
kemia or myelodysplastic syndrome (N23), thalassemia major
(N21), sickle cell anemia (N12) or other non-malignant
disorders (N9), and all but 4 received HLA-identical sibling
allografts. The median total nucleated (TNC) cell dose was
4.9  107 TNC/kg recipient weight (range, 1.1 – 24.1) and the
median CD34 cell dose was 1.6  105/kg (range, 0.1 – 6.9).
The median time to absolute neutrophil count 500 and plate-
let 20,000/mm3 was 22 and 45 days, respectively. Of 60 pa-
tients who could be evaluated, 2 (3%) had graft rejection and
both had a non-malignant disorder treated by a non-myeloab-
lative regimen. Fourteen of 56 evaluable patients (25%) devel-
oped Grades I-III acute graft-versus-host disease (GVHD) and
none had Grade IV GVHD. Two of 48 evaluable patients had
chronic GVHD (4.2%) and both received HLA-mismatched
allografts. Overall, the Kaplan-Meier probabilities of survival
and event-free survival after sibling CBT are 80% and 76%,
respectively with a median follow-up of 16 months (range, 0.1 –
94 months). Patients died of relapse (N7), pulmonary toxicity
(N2), seizures (N1), or sepsis (N1) with an overall TRM of
6%. Outcome after CBT was best in patients with non-malig-
nant conditions, where 39 of 42 survive after CBT (93%) and 37
of 42 (88%) survive free of the underlying disorder. These
results conﬁrm the utility of remote site, directed donor cord
blood collection and subsequent transplantation for hematolog-
ical disorders. The ability to combine cord blood with a marrow
harvest from sibling donors generated a low risk of graft rejec-
tion and very low rates of severe GVHD. Transplantation of
sibling CBUs in lieu of bone marrow may be especially advan-
tageous when there is urgency for transplantation and in non-
malignant disorders where GVHD, in particular, has a negative
impact upon outcome.
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HIGH AVIDITY CYCLIN E-DERIVED PEPTIDE-SPECIFIC CTL CONTRIB-
UTE TO INDUCTION OF REMISSION AFTER STEM CELL TRANSPLANTA-
TION
Ishiyama, K.1, Kondo, Y.1,2, Wieder, E.1, Lu, S.1, Molldrem, J.1 1De-
partment of Stem Cell Transplantation and Cellular Therapy, The
University of Texas M.D. Anderson Cancer Center, Houston, TX;
2Cellular Transplantation Biology, Kanazawa University Graduate
School of Medical Sciences, Kanazawa, Ishikawa, Japan.
Cyclin E1 (CCNE1) and cyclin E2 (CCNE2) are cell cycle genes that
are overexpressed in AML, ALL, and CML, and in solid tumors such as
breast cancer (BrCA), lung cancer, and gastric cancer. We found that
cytotoxic T-lymphocytes (CTL) with speciﬁcity for two HLA-A2-re-
stricted CCNE1 (CCNE1144-152, ILLDWLMEV) and CCNE2
(CCNE2144-152, ILLDWLLEV) peptides killed tumors that overex-
pressed either protein, including ALL, CML, and non-Hodgkin’s lym-
phoma (NHL). Peptide/HLA-A2 tetramer binding assays and dissocia-
tion studies showed antigen cross-recognition, although CCNE1
appearedmore dominant. To determine the clinical signiﬁcance of CTL
immunity to these self-epitopes, we studied 18 leukemia patients (10
CML, 8 ALL) and 3 breast cancer patients before and after allogeneic
stem cell transplantation (SCT) using peptide/HLA-A2 tetramers. A
two-fold increase in CCNE1- or CCNE2-CTL after SCT was consid-
ered as evidence of an immune response (IR). Amongst 18 leukemia
patients, an IR to CCNE1 or to CCNE2 was found in 12 (67%) and 14
(78%) patients, respectively. All 12 patients with an IR to CCNE1 also
had an IR to CCNE2, reﬂecting possible cross-recognition of both
peptides by some CTL clones. IR to either CCNE1 or CCNE2 did not
correlate with diagnosis, source of the graft, or disease status prior to
SCT. Importantly, IR correlated with complete remission (CR) after
SCT (100% vs. 33%; p0.04), but IR occurred more frequently in
patients without graft-versus-host disease (GVHD) (92% vs. 50%,
p0.05). One BrCA patient had no clinical response and no IR after
SCT; however, two BrCA patients showed both clinical responses and
IRs to both cyclin peptides after SCT. One of these latter patients also
developed concomitant GVHD after tacrolimus withdrawal. In all 3
patients, CTL immunity to CMV did not change in proportion to
clinical response after SCT, suggesting that tumor-speciﬁc immunity
developed to cyclin E. These results provide clinical evidence that both
CCNE1 and CCNE2 peptides are novel tumor-associated antigens, and
they justify future studies to determine whether CTL immunity can be
enhanced against these antigens in cancer patients. Moreover, IR to
CCNE1 and CCNE2 correlates with SCT-induced remission in the
absence of acute GVHD, suggesting that the graft-versus-tumor effect
may be separable from GVHD.
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ENHANCING THE IN VIVO EXPANSION OF ADOPTIVELY TRANSFERRED
EBV-CTL WITH LYMPHODEPLETING CD45 MONOCLONAL ANTIBODIES
IN NPC PATIENTS
Louis, C.U.1, Straathof, K.1, Torrano, V.1, Huls, M.H.1,
Gresik, M.V.1, Weiss, H.1, Gee, A.1, Brenner, M.K.1, Rooney, C.M.1,
Heslop, H.E.1, Gottschalk, S.1 1Center for Cell and Gene Therapy:
Baylor College of Medicine, The Methodist Hospital and Texas Chil-
dren’s Hospital and Cancer Center, Houston, TX.
Background: Treatment of Epstein Barr virus (EBV)-positive naso-
pharyngeal carcinoma (NPC) with polyclonal EBV-speciﬁc cytotoxic T
cells (EBV-CTL) has been promising, producing disease stabilization and
complete remissions in patients with low disease burden. However, in-
fused EBV-CTL did not expand signiﬁcantly in vivo, limiting their anti-
tumor activity. One strategy to enhance the in vivo expansion of adop-
tively transferred CTL is to reduce the lymphocyte pool prior to T cell
infusion. This should result in homeostatic proliferation of the infused T
cells restoring the lymphoid compartment. A pair of monoclonal anti-
bodies, targeted to the CD45 antigen (CD45 MAbs), were used to
selectively lymphodeplete patients prior to stem cell transplantation.
These produced marked reduction in circulating lymphoid and myeloid
cells while largely sparing marrow progenitors. We therefore hypothe-
sized that administration of CD45 MAbs will lymphodeplete NPC pa-
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